Liraglutide is an active pharmaceutical ingredient that has been used to produce injectable drugs since 2010. The first Liraglutide-containing drug was approved by the FDA in January 2010. At the US pharmacies, this drug is sold under the brand Victoza.
For more than 5 years, Victoza (Liraglutide) injections are prescribed to improve glycemic control in obese Americans aged 18 and older. Each milliliter of Victoza solution contains 6mg of active substance Liraglutide.
The same dose of Liraglutide is contained in Saxenda injectable solution, which appeared at the US pharmaceutical market in April 2015. Victoza and Saxenda injectable drugs contain the same doses of Liraglutide, but they were approved for the treatment of different diseases.
Victoza is prescribed only to diabetic patients, but Saxenda solution is approved for weight loss in patients with BMI of 27 and more. It should be noted that Saxenda drug could be prescribed to patients, whose obesity is associated with type 2 diabetes.
Given the fact that active ingredient Liraglutide stimulates the insulin secretion and reduces the blood glucose level, diabetic patients using Saxenda (Liraglutide) for weight loss may require dose reduction of antidiabetic drugs.
How does Liraglutide help to reduce body weight?
The structural formula and effects of active substance Liraglutide are similar to the formula and effects of natural hormone GLP-1. In human body, this hormone is produced in response to food intake.
During clinical trials, it was established the fact that regular subcutaneous administration of Liraglutide helps to reduce hunger and to increase saturation.
Researchers suppose that Liraglutide injections stimulate the regions of the brain regulating hunger and saturation like oral anorectics.
Herewith, Liraglutide has an undeniable advantage over oral anorectic drugs. After all, providing anorexigenic and antidiabetic effects, it helps lose weight and simultaneously reduce the risk of type 2 diabetes.
Some facts of the results of Saxenda (Liraglutide) clinical trials
The results of clinical trials have demonstrated that:
- About 50% of patients, used Saxenda for 3 years, were able to reduce their body weight by at least 5% of the original.
- About 25% of obese people, used Saxenda for 3 years, reduced their body weight by at least 10% of original.
- About 13% of participants of clinical trials stopped using Saxenda because of severe side effects.
After the successful completion of the long-term clinical trials of Saxenda, Novo Nordisk company has sent the results of this study in the FDA (US), EMA (EU), Health Canada and National Food and Drug Administrations of dozens of other countries around the world.
Having studied the results of clinical trials, the US FDA has concluded that the benefits of Saxenda for the health of obese patients outweigh potential risks. Thus, the FDA has approved Saxenda as an obesity treatment and Novo Nordisk has received the marketing authorization for Saxenda in the USA.
In the middle of 2015, new injectable weight loss drug – Saxenda (Liraglutide) has already been approved in the USA, Canada and Europe. However, the launch of Saxenda sales was announced only in the USA. Thus, in the near term we should expect the start of Saxenda sales in Canada and all 28 EU member states.